integrity and availability. The Confidentiality is
necessary to ensure that patient data is protected and
cannot be accessed by unauthorized persons,
whether accidental or deliberately. The Availability
is necessary to preserve the resources and services of
healthcare ISs that must be accessible when needed,
particularly in emergency or intensive care
situations. The Integrity is necessary to ensure that
clinical information stored or in transit is not
corrupted or changed improperly by unauthorized
users or through operational errors (in the
introduction and manipulation of data), software
bugs, viruses or equipment malfunction (ISO, 2006).
Since 1997, European legislation regulates the
protection and treatment of confidentiality, integrity
and availability of medical data trough
“Recommendation No. R (97) 5 of the Committee
of Ministers to Member States on the Protection of
Medical Data”, which stated in Principle 3.1 that
“The respect of rights and fundamental freedoms,
and in particular of the right to privacy, shall be
guaranteed during the collection and processing of
medical data” (Rec, 1997). This European
recommendation was the basis for the creation of
specific legislation in each Member State.
Since 1996, American legislation, through
Federal Law 104-191, known as the “Health
Insurance Portability and Accountability Act of
1996” - HIPAA (HIPAA, 1996) rules privacy,
information security and standards of all entities
providing healthcare or having access to data from
healthcare units. For this legislation, two regulation
documents were created. They provide a set of best
practices that healthcare institutions must follow in
order to guarantee a minimum level of information
security. These documents are called Security Rule
(2003) and Privacy Rule (2002) that rules the
organizations in the use and disclosure of
confidential, personal and identifiable health
information about patients that is designated
“Protected Health Information” (PHI). The PHI
includes information such as demographic data that
is utilized for the user identification, data from their
past, present or future health status and data related
with the healthcare services.
3 EUROPEAN LEGISLATION VS
AMERICAN LEGISLATION
European legislation is a comprehensive law,
implemented by supervision, which creates
European directives and recommendations that are
followed by the Member States trough the creation
of national legislation. The right to privacy is
explicit in the Charter of Fundamental Rights. One
the other hand, American legislation is a specific
law, implemented by different mechanisms, which
creates the federal law that is followed by the United
States of America. The right to privacy is not
explicit in the Constitution.
Another relevant difference is concerned about
the regulation of the legislation. In Europe this
adjustment is made by authority Supervisors such as
the European Data Protection Supervisor (EDPS),
the Europol Joint Supervisory Body and the
Schengen Joint Supervisory Authority. Within each
Member State there is an authority for the data
protection that should create recommendations and
ensure its compliance. In American legislation, it is
assumed that organizations govern themselves
autonomously.
For this comparative analysis a selection
regarding the security issues of clinical data was
made of both legislations. In the European
legislation, it was selected the chapter 9.2 of the
“Recommendation No. R (1997) 5” and in relation
to American legislation this study focused on the
Security Rule document from HIPAA.
Table 1, presents the analysis of clinical data
security recommendations from both legislations and
some examples and their descriptions of
technologies or mechanisms that could have
applicability in the different types of control, at the
level of: the physical entrance to installations, data
media, memory, utilization, access, communication,
data introduction, transport and availability.
4 DISCUSSION
Regarding the security of personal information the
authors consider that the European legislation has
the advantage of being: (1) a good reference model
for the good practice with flexibility in the
recommendations to Member States; (2)
technologically neutral; and (3) with an increased
awareness and concern about the security of clinical
data. However, European legislation presents some
weaknesses, such as for instance: (1) the dubious
association between certain key concepts (“personal
data” and “real privacy”); (2) the difficulties in
practical implementation due to the inconsistent role
of data protection authorities; and (3) the outdated
rules in transferring information to other countries.
Moreover, most Member States are governed by
national rules of clinical data protection and the
harmonization remains more apparent than real. This
HEALTHINF 2011 - International Conference on Health Informatics
568